OPEN-ANGLE GLAUCOMA

This early-stage study tested a tiny implant placed inside the eye that slowly releases medication to lower eye pressure in people with mild-to-moderate open-angle glaucoma. The goal was to find a safe and effective dose that reduces pressure by more than 20% with few side effect…

This study tested two new eye drops (AR-17043 and a combination with latanoprost) to see if they safely lower eye pressure in people with open-angle glaucoma or high eye pressure. A total of 426 adults took part. The goal was to find the best dose for reducing pressure, which is …

This study tested whether aiming a laser (SLT) at the nasal or inferior part of the eye works better to lower pressure in open-angle glaucoma. 13 adults with high eye pressure received one of the two treatments. The main goal was to see which location reduces eye pressure more ef…

This study tested a gel stent implant placed outside the eye to lower eye pressure in people with open-angle glaucoma. About 74 adults aged 45 and older took part. The goal was to see if the stent safely reduces eye pressure by at least 20% while using the same or fewer glaucoma …

This study tested a small device called the Hydrus Microstent in 217 adults with open-angle glaucoma that was not well controlled with medication. The goal was to see if the implant could safely lower eye pressure and reduce the number of eye drops needed. Results showed that man…

This study tested a new eye drop called Reformulated PG324 to see how safe and effective it is at lowering eye pressure in people with open-angle glaucoma or ocular hypertension. About 489 participants took part. The goal is to help control the disease and prevent vision loss, bu…

This study tested a new eye drop, NCX 470, against a standard treatment (latanoprost) in 696 people with open-angle glaucoma or high eye pressure. Participants used the drops once daily for up to 12 months. The main goal was to see how well NCX 470 lowers eye pressure compared to…

This study looked at how NCX 470 eye drops affect fluid movement inside the eye. 18 healthy volunteers or people with high eye pressure received the drops or a placebo for 8 days. Researchers measured fluid flow and drainage to understand how the drops work.